GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations Leukemia (2013) 27 1588-1592; doi:10.1038/leu.2012.346
Acute myeloid leukemia (AML) is a heterogeneous disease with variable treatment outcome. Despite recent advances in understanding the key molecular mechanisms of myeloid leukemogenesis, risk stratification remains imperfect, particularly in the intermediate risk group in which a large proportion of patients have a normal karyotype. For this group of patients, genetic alterations in genes, such as FLT3, NPM1 and CEPBA, provide useful prognostic information, but alone are not sufficient to accurately predict prognosis for all patients. Recently, recurrent mutations in epigenetic modifiers such as IDH1/2, 1 DNMT3A, 2 and TET2 3 have been described, but their prognostic significance remains somewhat controversial, and it is unclear if targeted therapies will evolve from identification of these mutations. 4 Identification of target genes that undergo epigenetic modification in the landscape of somatic mutations in epigenetic modifiers is likely to yield important prognostic information, and potentially identify novel biomarkers of response to demethylating agents, which are currently showing promise in the treatment of AML.
Growth arrest and DNA-damage inducible alpha (GADD45A) is a tumour suppressor gene that has cell-type specific roles in cellular stress, coordinating DNA repair and de-methylation, cell cycle arrest and pro-apoptotic or pro-survival responses. 5, 6 Although downregulation of GADD45A has been linked to the presence of FLT3-ITD and FLT3-TKD mutants, 7 and recently with RUNX1 c-terminal mutations, 8 there is a broad downregulation of GADD45A in AML and other mechanisms associated with this remain to be determined. Previous studies in solid tumours have identified atypical methylation of GADD45A at four discrete CpG residues (CpG1-4) B700 bp upstream of the transcriptional start site, which correlates with gene expression and has been linked to tumour response in vitro and in xenograft models. 7, [9] [10] [11] Here, we assessed DNA methylation of these same key CpG residues in GADD45A in AML and determined co-occurrence with other recurrent mutations and impact on patient outcome.
To determine the frequency of GADD45A CpG1-4 methylation in AML, we screened a retrospective cohort of 222 newly diagnosed AML cases for methylation of GADD45A CpG1-4 using Sequenom MassARRAY on bisulphite converted genomic DNA (amplicon given in Figure 1a ). All patients were collected with informed consent with approval from the relevant ethics committees, in accordance with the Declaration of Helsinki. The levels of GADD45A CpG1-4 methylation in the patient samples ranged from 0-90% ( Figure 1b) . As CpG1 methylation was always higher than CpG2-4 methylation it was considered representative of methylation at this discrete region, and GADD45A CpG1 hypermethylation (G45Ame high ) was defined as methylation exceeding 2 s.d. from the mean of the eight normal bone marrow and three normal CD34 þ pooled controls (X12%; Figure 1b ). Using this cutoff, 93 of 222 AML patients (42%) were defined as G45Ame high ( Figure 1b ; Table 1 ). G45Ame high patients were significantly older than G45Ame low patients with a mean age of 60 vs 55 years (P ¼ 0.02; Table 1 ). There was also a sex bias with significantly more females than males in the G45Ame high group. Additionally, we found a negative association of G45Ame high with Inv16 AML (P ¼ 0.006; Table 1 ).
To assess co-occurrence with other common mutations in AML we used a PCR-based fragment analysis for FLT3-ITD screening and a multiplexed matrix-assisted laser desorption/ionization time-offlight genotyping approach (Sequenom MassARRAY Compact System, Sequenom, Inc., San Diego, CA, USA) for detection of the following mutations:
, KRAS (G12D/V/A, G13D/A) and WT1 (rs16754). Mutation frequencies are given in Table 1 . We subsequently assessed co-association of recurrent mutations with GADD45A methylation status. Interestingly, there was a significant association of G45Ame high with IDH1/ 2 (Po0.0001) and DNMT3A (P ¼ 0.02) mutations (Table 1 , Figure 1c ). IDH1 and IDH2 mutations were mutually exclusive as reported previously, 1 and 36 of 41 patients (88%, Po0.0001) with either IDH1 or IDH2 mutations were in the G45Ame high patient group (Figure 1c ). For DNMT3A, 19 of 30 patients were associated with the G45Ame high patient group (63%, P ¼ 0.02). We found no statistical association of G45Ame high with FLT3-ITD or other recurrent mutations, and 13 of 93 (14%) G45Ame high patients were negative for all mutations tested.
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Letters to the Editor Table 1 . Distribution of GADD45A methylation in the overall AML and treated AML patient cohorts (2) 2 (2) 3 (3) 5 (3) 2 (2) 3 (5) M1 41 (18) 21 (16) 20 (22) 35 (21) 20 (19) 15 (24) M2 55 (25) 33 (26) 22 (24) 45 (27) 27 (25) 18 (30) M3 14 (6) 3 (2) 11 (12) (18) 22 (17) 18 (19) 29 (17) 16 (15) 13 (21) M5 15 (7) 9 (7) 6 (6) 11 (7) 7 (7) 4 (7) M6 6 (3) 5 (4) 1 (1) 4 (2) 4 (4) (26) 12 (13) 38 (23) 30 (28) 8 ( (43) 58 (45) 38 (41) 78 (47) 51 (48) 27 (44) t (11q23) 8 (4) 5 (4) 3 (3) 8 (5) 5 (5) 3 (5) inv (16) 14 (6) 8 (6) 6 (7) 11 (7) 7 (6) 4 (7) þ 8
13 (6) 9 (7) 4 (4) 9 (5) 5 (5) 4 (7) t (8;21) 3 (1) 2 (2) 1 (1) 2 (1) 2 (2) 0 (0) Complex 32 (14) 21 (16) 11 (12) 25 (15) 16 (15) 9 (14) Other 41 (19) 16 (12) 25 (27) 0.008 c 25 (15) 11 (10) 14 ( (12) 15 (12) 11 (12) 12 (7) 10 (10) 2 ( (5) 1 (1) 8 (5) 7 (7) 1 (2) Abbreviations: AML, acute myeloid leukemia; FAB, French-American-British classification; NS, not significant; WBC, white blood cell. Blast count indicates bone marrow blasts at diagnosis. Given the functions of GADD54A as a tumour suppressor gene and a known role in mediating response to cytotoxic agents, we next investigated the prognostic impact of G45Ame high in AML. Survival analysis was conducted on all 167 patients that received standard induction chemotherapy and for which clinical follow-up data were available (Table 1 ; treatment cohort). Briefly, patients under 60 years of age received chemotherapy regimes with idarubicin and high-dose cytarabine, and patients over 60 received idarubicin and standard dose cytarabine. Patients with acute promyelocytic leukaemia (n ¼ 14) were treated with All-trans retinoic acid and were excluded from survival analyses. Consolidation therapy consisted of high-dose cytarabine alone or standard dose cytarabine with idarubicin. In the treatment cohort, there were no significant differences in the baseline clinical characteristics of patients with respect to age, white blood cell count, blast count or sex (Table 1 ). Similar to the overall cohort, G45Ame high patients in the treatment cohort were significantly associated with IDH1/2 mutations (Po0.0001) and DNMT3A mutations (P ¼ 0.02), while displaying a negative association with the Inv(16) karyotype (P ¼ 0.03).
For survival analysis, overall survival (OS) was the primary endpoint and was defined as the time from date of diagnosis to date of death (failure) or last date of contact (censored). All patients still alive were censored at 5 years and the median age of follow-up was 3.8 years. Univariate analysis using a Cox regression model revealed that compared with G45Ame low patients, G45Ame
high patients had significantly shorter OS (median OS; 10 months vs 25 months, P ¼ 0.002, Figure 1d ). G45Ame high was also a significant predictor of shorter OS in intermediate risk AML, and this survival profile was similar to that of adverse risk AML (Figure 1e ). Intermediate risk G45Ame
high AML patients had a significantly shorter median OS of 11 months when compared with 33 months for G45Ame low patients (Figure 1f , P ¼ 0.004). We next looked at the subgroup of intermediate risk AML patients without FLT3-ITD or NPM1 mutations, as the risk profile of this group of patients is complex to stratify. We found that G45Ame high was able to segregate risk in this subgroup of patients with an OS of 7 months compared with 45 months for the G45Ame high patients (Figure 1g , P ¼ 0.014). Although the patient numbers are small, we also found that G45Ame high segregated outcome in NPM1 mut /FLT3-ITD WT AML (Figure 1h , P ¼ 0.02). We found no prognostic value in intermediate cytogenetic risk patients with FLT3-ITD mutations (data not shown).
Finally, we performed a multivariate analysis using a Cox proportional hazards model for OS, which included variables that were significant or approached significance in univariate analysis. The final model included the following variables: GADD45A CpG1 methylation status (high X12%/low o12%), age (o60 years vs X60 years), white cell count (WCC: (o50 Â 10 (Figure 1i ). We found that G45Ame high was an independent poor prognostic factor overall in AML (P ¼ 0.046), in the intermediate risk patient group (P ¼ 0.027), and approached significance in intermediate risk AML without FLT3-ITD or NPM1 mutations (P ¼ 0.051).
We observed that a large proportion of patients with IDH1/2 and DNMT3A mutations were G45Ame high , however the ability to G45Ame high to predict poor outcome was independent of IDH1/2 and DNMT3A mutation status, suggesting that GADD45A hypermethylation may be detecting a broader epigenetic phenotype. There was a significant proportion of G45Ame high patients in which there were no mutations detected that are known to affect DNA methylation. It is possible that these patients may have TET2 mutations, which affect the same pathway and have been shown to be mutually exclusive with IDH1/2 mutations, 1 or are associated with as-yet-unidentified mutations in epigenetic modifiers, and it will be important to test this in larger patient cohorts. This is the first study to link GADD45A promoter methylation to clinical outcome in cancer. We show that the G45Ame high patient group represents a large proportion of AML patients, which have a significantly poorer OS, particularly in the intermediate risk subgroup. As stratification of this group is critical, methylation of this single CpG residue represents a novel marker that could potentially provide important prognostic information. The poor outcome observed in G45Ame high patients is consistent with a direct role for GADD45A silencing in chemo-responsiveness and known functions of GADD45A. 6, 8, 12 As demethylating agents have shown some efficacy as a single agent in poor risk, relapsed, and resistant AML 13, 14 and more recently as a priming agents before standard induction chemotherapy in AML, 15 it will now be important to test if G45Ame high can predict response to these agents.
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Murine mantle cell lymphoma model cell line Mantle cell lymphoma (MCL) 1 is characterized by dysregulated expression of cyclin D1 due to the cytogenetic translocation t(11;14)(q13;q32).
2 Cyclin D1 interaction with cyclin-dependent kinases (cdk) drives cells through the G1-S checkpoint. Nonetheless, cyclin D1 overexpression in mouse B cells is not sufficient to induce lymphoma and cyclin D1 is necessary, but not sufficient, to produce MCL. 3 While therapeutic advances have prolonged survival in MCL, 4 with many novel agents in development, optimizing combinations would benefit from an animal model. MCL cell lines generally represent blastoid or atypical variants. 5 Two recently reported mouse models of blastoid MCL, one based on interleukin-14/myc double transgenics, 6 the other on combined abnormalities of INK4A and myc, 7 may provide biological insights and testing for blastoid MCL. Transgenic mice expressing cyclin D1 in B cells are healthy. 3 We previously demonstrated that these mice do develop lymphoma with MCL characteristics if their immune system is non-specifically stimulated by pristane when they are older. 8 This system can provide biologic insights into genetic events cooperating with cyclin D1. 9 Unfortunately, the aging requirement makes this model cumbersome for therapeutic testing. Here we report that the FC-muMCL1 cell line established from a pristane-induced lymphoma, grows in young syngeneic mice, has associated immune cell infiltration, and provides a means to test novel targeted therapies against lymphomas constitutively overexpressing cyclin D1.
